Cargando…

Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study

BACKGROUND: Multiple myeloma is a cancer in the bone marrow causing bone destruction. Patients experience various symptoms related to the disease and/or treatment, such as pain and fatigue, leading to poorer quality of life. The symptom burden might affect physical function and physical activity lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larsen, Rikke Faebo, Jarden, Mary, Minet, Lisbeth Rosenbek, Frølund, Ulf Christian, Möller, Sören, Abildgaard, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055017/ https://www.ncbi.nlm.nih.gov/pubmed/32126972 http://dx.doi.org/10.1186/s12885-020-6637-6

Ejemplares similares

Supervised and home-based physical exercise in patients newly diagnosed with multiple myeloma—a randomized controlled feasibility study
por: Larsen, Rikke Faebo, et al.
Publicado: (2019)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

Multiple Myeloma Associated Bone Disease
por: Rasch, Stine, et al.
Publicado: (2020)

The Danish National Multiple Myeloma Registry
por: Gimsing, Peter, et al.
Publicado: (2016)

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study
por: Gregersen, Henrik, et al.
Publicado: (2017)

The effect of an interdisciplinary rehabilitation intervention comparing HRQoL, symptom burden and physical function among patients with primary glioma: an RCT study protocol
por: Hansen, Anders, et al.
Publicado: (2014)

The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey
por: Redder, Louise, et al.
Publicado: (2021)

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
por: Gregersen, Henrik, et al.
Publicado: (2018)

Symptoms of total pain experienced by older people with advanced gastrointestinal cancer receiving palliative chemotherapy
por: Jespersen, Eva, et al.
Publicado: (2022)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation
por: Andersen, Morten Nørgaard, et al.
Publicado: (2017)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Harnessing the Immune System to Fight Multiple Myeloma
por: Krejcik, Jakub, et al.
Publicado: (2021)

Physical, mental, and social functioning in women age 65 and above with and without a falls history: An observational case-control study
por: Minet, Lisbeth Rosenbek, et al.
Publicado: (2018)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma: Erratum
Publicado: (2016)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
por: Rifkin, Robert M., et al.
Publicado: (2019)

A simple additive staging system for newly diagnosed multiple myeloma
por: Abdallah, Nadine H., et al.
Publicado: (2022)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients
por: Mielnik, Michał, et al.
Publicado: (2023)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Elevation of Serum Ferritin is Associated with the Outcome of Patients with Newly Diagnosed Multiple Myeloma
por: Song, Moo-Kon, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_fu8u70bbt2l1aruui7csugb359